Clinical • Trial completion • Trial completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG2 (Cancer/testis antigen 2)
|
EGFR mutation • ALK rearrangement • CTAG2 expression
|
fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous